Impact Biomedical Completes Merger; Zoar Shareholder Gains About 94% Control

The shares will stop trading under IBO and are expected to reappear as ZOAR on NYSE American on Nov. 18, with the Zoar shareholder holding about 94% of the new parent.

Pharmaceutical factory workers in sterile environment
Photo: Desizned/Shutterstock.com

Key points

  • Merger closed Nov. 17; holders received 8,640,000 PubCo shares, about 4.80% of the total
  • Zoar shareholder Kanans Visvanats holds about 94.02% of PubCo's shares
  • IBO delisting takes effect 10 days after Form 25; shares expected to trade as ZOAR
  • Net loss was $11.8 million for 2025; cash was $21 thousand at Sept. 30, 2026

Impact Biomedical Inc. (NYSE American: IBO) completed its merger into a subsidiary of PubCo on Nov. 17, the company said in an 8-K filed Wednesday. The company became a wholly owned subsidiary of PubCo, and the Zoar shareholder, Kanans Visvanats, now controls a majority of the voting power of PubCo and, indirectly, of Impact Biomedical.

Stockholders receive PubCo shares, not cash

Under the merger agreement, each share of Impact Biomedical common stock was converted into one PubCo ordinary share after a 1-for-12.62 reverse split took effect. Holders of the common stock received 8,640,000 PubCo ordinary shares in total, about 4.80% of PubCo's shares outstanding at closing. The company said PubCo paid no cash consideration.

The company's stockholders approved the merger at a special meeting on Nov. 13. Impact Biomedical's articles and bylaws were also replaced with those of the merger subsidiary, and the company was renamed Dr Ashleys USA Inc.

Control shifts to a small group of holders

In the share exchange, PubCo issued 167,976,000 ordinary shares to the Zoar shareholder, about 94.02% of the total at closing. It also issued 1,800,000 shares to BMI Capital International LLC, about 1.00%, and 228,000 shares to DSS, Inc. Frank D. Heuszel, Impact Biomedical's chief executive, received 22,000 compensation shares.

The board and officers changed at the effective time. Each director, the chief financial officer and the chief operating officer resigned. PubCo appointed eight directors, including Visvanats as chairman. Visvanats is also PubCo's chief executive and interim chief financial officer.

Delisting and a new ticker

Impact Biomedical asked NYSE American to suspend trading before the open on Nov. 18, withdraw its common stock from listing and file a Form 25. The delisting takes effect ten days after the Form 25 is filed. The company then intends to file a Form 15 to deregister its common stock and suspend certain reporting obligations.

The PubCo shares are expected to begin trading on NYSE American under the symbol ZOAR on Nov. 18.

Losses narrowed, but cash was small

For 2025, revenue was $32 thousand and the operating loss was $4.3 million, down from $28.8 million the year before. The net loss was $11.8 million, against $24.7 million in 2024.

In the quarter ended Sept. 30, 2026, revenue was $21 thousand, up 17% from a year earlier. The net loss was $0.6 million, compared with $1.5 million, or $1.52 a share, a year earlier; the latest quarter's loss was $0.08 a share. Cash was $21 thousand at Sept. 30.

Before the filing, the company's market value was about $53.3 million, based on 8.6 million shares as of Nov. 5 and the $6.17 close on Nov. 17. The share count has since changed because of the reverse split and the share issuance. The company did not say what PubCo's business plans are after the merger.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

More SEC filing stories

Mergers and acquisitions →
IBO page →

Filings, figures and price history are on the Impact Biomedical page.